+1-510-404-8135
The global vaccine market is anticipated to reach $103.57 billion by 2028, witnessing a CAGR of 11.02% in the forecast period 2018-2028.
Vaccines protect people against serious and potentially deadly diseases. They produce immunity by injecting components and agents inside the body. They greatly reduce the risk of infection by working with the natural defense of the body to safely develop immunity to a disease. Vaccines are developed based on the type of information of the disease. They are also developed for the control of endemic situation and at the time of outbreak of the disease. Adjuvants are used in the vaccine to improve the efficiency and increase the immune response to the vaccine. Moreover, there are several safety and efficacy issues involved with the vaccines. In order to overcome these problems, next-generation vaccines are developed. Next-generation vaccines are currently in the product pipeline which includes, DNA vaccines, recombinant viral vector vaccines, and individualized vaccines. Individualized vaccines are developed based on the phenotype and genotype immune response of an individual.
The purpose of this study is to gain a holistic view of the global vaccine market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global vaccine market. The market has been segmented into “product”, “disease”, “route of administration”, and “region”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the global vaccine market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global vaccine market. Moreover, the study includes detailed product mapping, market estimation and analysis of key trends in multiple geographical regions, growth of the vaccine market in each region for different cancer types, and the key strategies and developments by the prominent vaccine market stake holders.
The answers to the following key questions can be derived from this report:
• What are the major market drivers, challenges, and opportunities in the global vaccine market?
• What are the underlying structures resulting in the emerging trends within the vaccine industry?
• What were the market values of the leading segments and sub-segments of the global vaccine market in 2017?
• How will each segment of the global vaccine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period 2018-2028?
• What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?
• What are the key vaccine type in vaccine market? What are the major benefits of each type?
• How has the market been segmented on the basis of disease type? Which disease type is dominating the global vaccine market, and what is the reason behind its domination?
• What are the market shares of each of the companies in the global vaccine market, and what are their contribution?
• Who are the key manufacturers in the global vaccine market, and what are their contributions?
• What is the scope of each vaccine type, route of administration, and disease type in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?
• What are the key regulatory implications in developed and developing regions for vaccines?
• What is the growth potential of vaccine in each region, including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?
• Which vaccine type is having the most promising growth and in which disease type?
The key players who have been contributing significantly to the global vaccine market are Merck &Co., Inc., GlaxoSmithKline plc, Abbott Laboratories, Bavarian Nordic, Janssen Pharmaceutical NV, Pfizer, Inc., Sanofi Pasteur SA, and Seqirus (a CSL company), among others.
List of Tables
Table 2.1 Impact Analysis
Table 2.2 Vaccination Coverage (by Vaccine and WHO Region) - Worldwide, 2016
Table 3.1 Number of Mergers and Acquisitions (by Each Company), January 2015-September 2018
Table 3.2 Number of Business Expansion (by Each Company), January 2015-September 2018
Table 4.1 The European Medicines Agency’s Scientific Guidelines on Vaccines
Table 4.2 Regulatory Scenario Across the World
Table 7.1 Global Vaccine Market (by Disease Type), 2017-2028
Table 8.1 North America Vaccine Market (by Disease Type), 2017-2028
Table 8.2 Europe Vaccine Market (by Disease Type), 2017-2028 ($Billion)
Table 8.3 APAC Vaccine Market (by Disease Type), 2017-2028 ($Billion)
Table 8.4 Latin America Vaccine Market (by Disease Type), 2017-2028 ($Billion)
Table 8.5 Middle East and Africa Vaccine Market (by Disease Type), 2017-2028 ($Billion)
List of Figures
Figure 1 Global Vaccine Market Structure
Figure 2 Impact of Market Drivers and Market Restraints, 2017 and 2028
Figure 3 Global Vaccine Market Snapshot
Figure 4 Dominating Segments of Global Vaccine Market, 2017 and 2028
Figure 5 Global Vaccine Market (by Vaccine type), 2017 and 2028
Figure 6 Global Vaccine Market (by Route of Administration), 2017 and 2028
Figure 7 Global Vaccine Market (by Region), 2017 and 2028
Figure 8 Global Vaccine Market (by Region), 2017 and 2028
Figure 9 Market Statistics
Figure 10 Market Share Analysis: Global Vaccine Market, 2017
Figure 11 Opportunity Map Analysis of Next-generation Vaccines
Figure 1.1 Classification of Global Vaccine Market
Figure 1.2 Different Types and Generation of Vaccines
Figure 1.3 Components of a Vaccine
Figure 1.4 Evolution of Vaccines against Diseases
Figure 1.5 Global Vaccine Market, 2017-2028
Figure 2.1 Market Dynamics of Global Vaccine Market
Figure 3.1 Competitive Landscape, January 2015-September 2018
Figure 3.2 Share of Key Developments and Strategies, January 2015-September 2018
Figure 3.3 Product Launches Share (by Companies), January 2015- September 2018
Figure 3.4 Joint Ventures, Partnerships, and Collaborations Share (by Companies), January 2015-September 2018
Figure 3.5 Others Share (by Companies), January 2015-September 2018
Figure 3.6 Market Share Analysis: Global Vaccine Market, 2016 and 2017
Figure 3.7 Porter’s Five Forces Analysis
Figure 3.8 Bargaining Power of Suppliers: Overall Impact, 2015-2028
Figure 3.9 Bargaining Power of Buyers: Overall Impact, 2015-2028
Figure 3.10 Threat of New Entrant: Overall Impact, 2015-2028
Figure 3.11 Threat of Substitute Products: Overall Impact, 2014-2028
Figure 3.12 Intensity of Competitive Rivalry: Overall Impact, 2015-2028
Figure 4.1 Industry Insights, January 2015-May 2018
Figure 4.2 Regulatory Pathway from Preclinical to the Marketing Authorization
Figure 4.3 Pipeline Analysis
Figure 4.4 Pipeline Analysis According to Clinical Trial Phases
Figure 5.1 Global Vaccine Market (by Route of Administration)
Figure 5.2 Global Vaccine Market (by Route of Administration), 2017-2028
Figure 5.3 Global Vaccine Market (by Intramuscular), 2017-2028
Figure 5.4 Global Vaccine Market (by Subcutaneous), 2017-2028
Figure 5.5 Global Vaccine Market (by Oral Vaccine), 2017-2028
Figure 5.6 Global Vaccine Market (by Intravenous vaccine), 2017-2028
Figure 5.7 Global Vaccine Market (by Others), 2017-2028
Figure 6.1 Global Vaccine Market (by Type)
Figure 6.2 Global Vaccine Market (by Type), 2017-2028
Figure 6.3 Global Vaccine Market (by Subunit and Conjugate), 2017-2028
Figure 6.4 Global Vaccine Market (by Live Attenuated), 2017-2028
Figure 6.5 Global Vaccine Market (by Inactivated), 2017-2028
Figure 6.6 Global Vaccine Market (by Recombinant), 2017-2028
Figure 6.7 Global Vaccine Market (by Toxoid), 2017-2028
Figure 6.8 Global Vaccine Market (by Next-Generation), 2021-2028
Figure 7.1 Global Vaccine Market (by Disease Type)
Figure 7.2 Global Vaccine Market (by Pneumococcal Disease), 2017-2028
Figure 7.3 Global Pneumococcal Disease Vaccine Market (by Region), 2017-2028
Figure 7.4 Global Vaccine Market (by DTP), 2017-2018
Figure 7.5 Global DTP Disease Vaccine Market (by Region), 2017-2028
Figure 7.6 Global Vaccine Market (by Influenza), 2017-2028
Figure 7.7 Global Influenza Vaccine Market (by Region), 2017-2028
Figure 7.8 Global Vaccine Market (by Cancer), 2017-2028
Figure 7.9 Global Cancer Vaccine Market (by Region), 2017-2028
Figure 7.10 Global Vaccine Market (by HPV), 2017-2028
Figure 7.11 Global HPV Vaccine Market (by Region), 2017-2028
Figure 7.12 Global Vaccine Market (by Meningococcal Disease), 2017-2028
Figure 7.13 Global Meningococcal Disease Vaccine Market (by Region), 2017-2028
Figure 7.14 Global Vaccine Market (by Hepatitis), 2017-2028
Figure 7.15 Global Hepatitis Disease Vaccine Market (by Region), 2017-2028
Figure 7.16 Global Vaccine Market (by MMR), 2017-2028
Figure 7.17 Global MMR Vaccine Market (by Region), 2017-2028
Figure 7.18 Global Vaccine Market (by Rotavirus), 2017-2028
Figure 7.19 Global Rotavirus Vaccine Market (by Region), 2017-2028
Figure 7.20 Global Vaccine Market (by Varicella), 2017-2028
Figure 7.21 Global Varicella Vaccine Market (by Region), 2017-2028
Figure 7.22 Global Vaccine Market (by Others), 2017-2028
Figure 8.1 Global Vaccine Market (by Region), 2017 and 2028
Figure 8.2 Global Vaccine Market (by Vaccine Market), 2017-2028
Figure 8.3 North America Vaccine Market, 2017-2028
Figure 8.4 North America: Market Dynamics
Figure 8.5 North America Vaccine Market (by Country), 2017-2028
Figure 8.6 North America Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.7 North America Vaccine Market (by Route of Administration), 2017-2028
Figure 8.8 U.S. Vaccine Market, 2017-2028
Figure 8.9 Canada Vaccine Market, 2017-2028
Figure 8.10 Europe Vaccine Market, 2017-2028
Figure 8.11 Europe: Market Dynamics
Figure 8.12 Europe Vaccine Market (by Country), 2017-2028
Figure 8.13 Europe Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.14 Europe Vaccine Market (by Route of Administration), 2017-2028
Figure 8.15 Germany Vaccine Market, 2017-2028
Figure 8.16 France Vaccine Market, 2017-2028
Figure 8.17 U.K. Vaccine Market, 2017-2028
Figure 8.18 Spain Vaccine Market, 2017-2028
Figure 8.19 Italy Vaccine Market, 2017-2028
Figure 8.20 Switzerland Vaccine Market, 2017-2028
Figure 8.21 Rest-of-Europe Vaccine Market, 2017-2028
Figure 8.22 APAC Vaccine Market, 2017-2028
Figure 8.23 APAC: Market Dynamics
Figure 8.24 APAC Vaccine Market (by Country), 2017-2028
Figure 8.25 APAC Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.26 APAC Vaccine Market (by Route of Administration), 2017-2028
Figure 8.27 China Vaccine Market, 2017-2028
Figure 8.28 India Vaccine Market, 2017-2028
Figure 8.29 Japan Vaccine Market, 2017-2028
Figure 8.30 Australia Vaccine Market, 2017-2028
Figure 8.31 South Korea Vaccine Market, 2017-2028
Figure 8.32 Rest-of-APAC Vaccine Market, 2017-2028
Figure 8.33 Latin America Vaccine Market, 2017-2028
Figure 8.34 Latin America: Market Dynamics
Figure 8.35 Latin America Vaccine Market (by Country), 2017-2028
Figure 8.36 Latin America Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.37 Latin America Vaccine Market (by Route of Administration), 2017-2028
Figure 8.38 Brazil Vaccine Market, 2017-2028
Figure 8.39 Mexico Vaccine Market, 2017-2028
Figure 8.40 Rest-of-Latin America Vaccine Market, 2017-2028
Figure 8.41 Middle East and Africa Vaccine Market, 2017-2028
Figure 8.42 Middle East and Africa: Market Dynamics
Figure 8.43 Middle East and Africa Vaccine Market (by Country), 2017-2028
Figure 8.44 Middle East and Africa Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.45 Middle East and Africa Vaccine Market (by Route of Administration), 2017-2028
Figure 8.46 GCC Vaccine Market, 2017-2028
Figure 8.47 South Africa Vaccine Market, 2017-2028
Figure 8.48 Rest-of- Middle East and Africa Vaccine Market, 2017-2028
Figure 9.1 Share of Key Company Profiled
Figure 9.2 Abbott India Ltd. (Subsidiary of Abbott Laboratories): Product Offerings for Global Vaccine Market
Figure 9.3 Abbott Laboratories: Overall Financials, 2015-2017
Figure 9.4 Abbott Laboratories: Revenue (by Business Segment), 2015-2017
Figure 9.5 Abbott Laboratories: Revenue (by Region), 2015-2017
Figure 9.6 Abbott Laboratories: R&D Expense, 2015-2017
Figure 9.7 Abbott Laboratories: Revenue Forecast, 2015-2020
Figure 9.8 Abbott Laboratories: SWOT Analysis
Figure 9.9 AstraZeneca plc: Product Offerings for Global Vaccine Market
Figure 9.10 AstraZeneca plc: Overall Financials, 2015-2017
Figure 9.11 AstraZeneca plc: Revenue (by Region), 2015-2017
Figure 9.12 AstraZeneca plc: R&D Expense, 2015-2017
Figure 9.13 AstraZeneca PLC: SWOT Analysis
Figure 9.14 BiondVax Pharmaceuticals Ltd.: Overall Financials, 2015-2017
Figure 9.15 BiondVax Pharmaceuticals Ltd.: R&D Expense, 2015-2017
Figure 9.16 BiondVax Pharmaceuticals Ltd.: SWOT Analysis
Figure 9.17 Bavarian Nordic: Overall Financials, 2015-2017
Figure 9.18 Bavarian Nordic: Revenue (by Region), 2015-2017
Figure 9.19 Bavarian Nordic: R&D Expense, 2015-2017
Figure 9.20 Bavarian Nordic: Revenue Forecast, 2015-2020
Figure 9.21 Bavarian Nordic: SWOT Analysis
Figure 9.22 CSL Limited: Product Offerings for Global Vaccine Market
Figure 9.23 CSL Limited: Overall Financials, 2015-2017
Figure 9.24 CSL Limited: Revenue (by Business Segment), 2015-2017
Figure 9.25 CSL Limited: Revenue (by Region), 2015-2017
Figure 9.26 CSL Limited: R&D Expense, 2015-2017
Figure 9.27 CSL Limited: Revenue Forecast, 2015-2020
Figure 9.28 CSL Limited: SWOT Analysis
Figure 9.29 Daiichi Sankyo Company, Limited: Product Offerings for Global Vaccine Market
Figure 9.30 Daiichi Sankyo Company, Limited: Overall Financials, 2015-2017
Figure 9.31 Daiichi Sankyo Company, Limited: Revenue (by Business Segment), 2015-2017
Figure 9.32 Daiichi Sankyo Company, Limited: Revenue (by Region), 2015-2017
Figure 9.33 Daiichi Sankyo Company, Limited: R&D Expense, 2015-2017
Figure 9.34 Daiichi Sankyo Company, Limited: Revenue Forecast, 2015-2020
Figure 9.35 Daiichi Sankyo Company, Limited: SWOT Analysis
Figure 9.36 Emergent BioSolutions Inc.: Product Offerings for Global Vaccine Market
Figure 9.37 Emergent BioSolutions Inc.: Overall Financials, 2015-2017
Figure 9.38 Emergent BioSolutions Inc.: Revenue (by Region), 2015-2017
Figure 9.39 Emergent BioSolutions Inc.: R&D Expense, 2015-2017
Figure 9.40 Emergent BioSolution Inc.: Revenue Forecast, 2015-2020
Figure 9.41 Emergent BioSolutions Inc.: SWOT Analysis
Figure 9.42 GlaxoSmithKline plc: Product Offerings for Global Vaccine Market
Figure 9.43 GlaxoSmithKline plc: Overall Financials, 2015-2017
Figure 9.44 GlaxoSmithKline plc: Revenue (by Business Segment), 2015-2017
Figure 9.45 GlaxoSmithKline plc: Revenue (by Region), 2015-2017
Figure 9.46 GlaxoSmithKline plc: R&D Expense, 2015-2017
Figure 9.47 GlaxoSmithKline plc: Revenue Forecast, 2015-2020
Figure 9.48 GlaxoSmithKline plc: SWOT Analysis
Figure 9.49 Product Offerings
Figure 9.50 Inovio Pharmaceuticals Inc.: Overall Financials, 2015-2017
Figure 9.51 Inovio Pharmaceuticals Inc..: R&D Expense, 2015-2017
Figure 9.52 Inovio pharmaceuticals Inc.: Revenue Forecast, 2015-2020
Figure 9.53 Inovio Pharmaceutical Inc.: SWOT Analysis
Figure 9.54 Johnson & Johnson: Product Offerings for Global Vaccine Market
Figure 9.55 Johnson & Johnson: Overall Financials, 2015-2017
Figure 9.56 Johnson & Johnson: Revenue (by Business Segment), 2015-2017
Figure 9.57 Johnson & Johnson: Revenue (by Region), 2015-2017
Figure 9.58 Johnson & Johnson: R&D Expense, 2015-2017
Figure 9.59 Johnson & Johnson: Revenue Forecast, 2015-2020
Figure 9.60 Johnson & Johnson: SWOT Analysis
Figure 9.61 Merck & Co. Inc.: Product Offerings for Global Vaccine Market
Figure 9.62 Merck & Co: Overall Financials, 2015-2017
Figure 9.63 Merck & Co. Inc..: Revenue (by Business Segment), 2015-2017
Figure 9.64 Merck & Co. Inc..: Revenue (by Region), 2015-2017
Figure 9.65 Merck & Co. Inc..: R&D Expense, 2015-2017
Figure 9.66 Merck & Co. Inc..: Revenue Forecast, 2015-2020
Figure 9.67 Merck & Co. Inc.: SWOT Analysis
Figure 9.68 Madison Vaccines Incorporated: SWOT Analysis
Figure 9.69 Pfizer, Inc.: Product Offerings for Global Vaccine Market
Figure 9.70 Pfizer, Inc.: Overall Financials, 2015-2017
Figure 9.71 Pfizer, Inc.: Revenue (by Business Segment) 2015-2017
Figure 9.72 Pfizer, Inc.: Revenue (by Region) 2015- 2017
Figure 9.73 Pfizer, Inc.: R&D Expense, 2015-2017
Figure 9.74 Pfizer, Inc.: Revenue Forecast, 2015-2020
Figure 9.75 Pfizer, Inc.: SWOT Analysis
Figure 9.76 Sanofi S.A.: Product Offerings for Global Vaccine Market
Figure 9.77 Pipeline Products
Figure 9.78 Sanofi S.A.: Overall Financials, 2015-2017
Figure 9.79 Sanofi S.A..: Revenue (by Business Segment), 2015-2017
Figure 9.80 Sanofi S.A.: Revenue (by Region), 2015-2017
Figure 9.81 Sanofi S.A.: R&D Expense, 2015-2017
Figure 9.82 Sanofi S.A..: Revenue Forecast, 2015-2020
Figure 9.83 Sanofi S.A..: SWOT Analysis
Figure 9.84 Sinovac Biotech Ltd.: Product Offerings for Global Vaccine Market
Figure 9.85 Sinovac Biotech Ltd..: Overall Financials, 2015-2017
Figure 9.86 Sinovac: Revenue (by Region), 2015-2017
Figure 9.87 Sinovac Biotech Ltd.: R&D Expense, 2015-2017
Figure 9.88 Sinovac Biotech Ltd.: Revenue Forecast, 2015-2020
Figure 9.89 Sinovac Biotech Ltd.: SWOT Analysis
Figure 9.90 Valneva SE: Product Offerings for Global Vaccine Market
Figure 9.91 Valneva SE.: Overall Financials, 2015-2017
Figure 9.92 Valneva SE: Revenue (by Business Segment), 2015-2017
Figure 9.93 Valneva SE: Revenue (by Region), 2015 & 2017
Figure 9.94 Valneva SE: R&D Expense, 2015-2017
Figure 9.95 Valneva SE: Revenue Forecast, 2015-2020
Figure 9.96 Valneva SE.: SWOT Analysis
Figure 9.97 VBI Vaccine Inc.: Product Offerings for Global Vaccine Market
Figure 9.98 VBI Vaccine Inc.: Overall Financials, 2015-2017
Figure 9.99 VBI Vaccine Inc. Revenue (by Region) 2015-2017
Figure 9.10 0 VBI Vaccine Inc.: R&D Expense, 2015-2017
Figure 9.10 1 VBI Vaccine Inc.: SWOT Analysis
Figure 10.1 Global Vaccine Market: Market Segmentation
Figure 10.2 Global Vaccine Market Segmentation
Figure 10.3 Primary Research
Figure 10.4 Secondary Research
Figure 10.5 Data Triangulation
Figure 10.6 Top-down Approach (Segment-wise Analysis)
Figure 10.7 Bottom-up Approach (Segment-wise Analysis)
Figure 10.8 Assumptions and Limitations
Figure 10.9 Considered Factors for Data Prediction and Modelling
There has been a continuous search in the medical world for better treatment and prevention approaches for various infectious and non-infectious diseases. This paved the way for the most awaited change in pediatric and adult vaccines. In the recent years, the impressive research on biologics for the development of DNA, recombinant, and cancer vaccines with better routes of administration, has opened new hopes to develop promising vaccines for different types of cancers, rare, and orphan diseases. Recent advancements in vaccine technologies especially in vaccine delivery platforms and ongoing clinical trials have resulted in the evolution of therapeutic as well as preventive vaccines.
Vaccines play a major role in developing immune responses by imitating an infection. Depending on the type of infection either caused by bacteria or virus, different approaches are used by the researchers to develop vaccines. Vaccines have been fruitful in the treatment and prevention of cancer and large pool of infectious diseases such as influenza, hepatitis, meningitis, rotavirus, human papilloma virus (HPV), and dengue, among others. Cancer, a global pandemic, is one of the leading causes of deaths worldwide. According to the research study conducted by the International Agency for Cancer Research, approximately 14.1 million new cancer cases were detected, and 8.2 million cancer deaths were reported in 2012. Moreover, considering the present prevalence rates, the number of cases detected are expected to grow over 21.7 million while the death counts are expected to reach 13 million. The rise in the count of cancer cases has been significantly increasing the global economic burden and was estimated at $1.16 trillion in 2010. The ongoing clinical trials for the development of cancer vaccines is aimed at enabling early diagnosis and treatment, thus consequentially aiding in combating cancer. Additionally, rising outbreaks of epidemic and zoonotic diseases in different parts of the globe has led to the development of preventive vaccines that helps occurrence and spread of these infections to a significant extent.
The purpose of this study is to gain a holistic view of the vaccine market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global vaccine market. The market has been segmented into “vaccine type”, “route of administration”, “disease type”, and “region”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
The global vaccine market is anticipated to reach $103.57 billion by 2028, witnessing a CAGR of 11.02% in the forecast period 2018-2028. Some of the factors such as growing prominence for the rising need for immunization coverage, substantial investments made in the field of research and development of novel vaccines and technologies, growing demand for cancer vaccines, and increasing incidence of infectious diseases and cancer coupled with rising geriatric population are acting as significant factors propelling the growth of the global vaccine market.
In terms of vaccine type, the global vaccine market is dominated by subunit and conjugate vaccine. Subunit and conjugate vaccines were developed when inactivated and killed vaccines failed to show significant results in the treatment and prevention of several diseases. Subunit vaccines can comprise from one to 20 antigens or more at times. Moreover, subunit vaccines use recombinant DNA technology as well for the antigen biomolecules from microbes. There are different types of subunit vaccines that are currently available in the market such as protein-based subunit vaccines, polysaccharide vaccines, and subunit conjugate vaccines. Furthermore, they are used in the treatment and prevention of large number of diseases such as influenza, hepatitis b, haemophilus influenza type B, pertussis, pneumococcal infections, and meningococcal diseases.
In terms of route of administration, the global vaccine market is dominated by intramuscular. In 2017, the market for intramuscular route of administration was valued $18.03 billion. Vaccines that are currently available in the market are majorly administered intramuscularly. Furthermore, this route of administration is effective for all age groups.
In terms of regional potential, North America is the leading contributor to the global vaccine market and contributed approximately 35% of the global market values in 2017. This can be attributed to high adoption rate of advanced technologies, increasing healthcare investments, presence of major manufacturers and increasing research and clinical trials by researchers and scientists for development of new vaccines across various universities in the region.
The key players who have been contributing significantly to the global vaccine market are Pfizer, Inc., Merck & Co., Inc., Emergent Biosolutions Inc., Abbott Laboratories, VBI Vaccines Inc., Madison Vaccines, Vical Inc., Inovio Pharmaceuticals Inc., GlaxoSmithKline plc, CSL Limited, AstraZeneca plc, LG Chem Ltd., Daiichi Sankyo Company, Limited, Sanofi S.A., Valneva SE, Bavarian Nordic, Sinovac Biotech Ltd., and Janssen Pharmaceutica NV, among others.
We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.
With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.
Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.
Vaccines protect people against serious and potentially deadly diseases. They produce immunity by injecting components and agents inside the body. They greatly reduce the risk of infection by working with the natural defense of the body to safely develop immunity to a disease. Vaccines are developed based on the type of information of the disease. They are also developed for the control of endemic situation and at the time of outbreak of the disease. Adjuvants are used in the vaccine to improve the efficiency and increase the immune response to the vaccine. Moreover, there are several safety and efficacy issues involved with the vaccines. In order to overcome these problems, next-generation vaccines are developed. Next-generation vaccines are currently in the product pipeline which includes, DNA vaccines, recombinant viral vector vaccines, and individualized vaccines. Individualized vaccines are developed based on the phenotype and genotype immune response of an individual.
The purpose of this study is to gain a holistic view of the global vaccine market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global vaccine market. The market has been segmented into “product”, “disease”, “route of administration”, and “region”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the global vaccine market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global vaccine market. Moreover, the study includes detailed product mapping, market estimation and analysis of key trends in multiple geographical regions, growth of the vaccine market in each region for different cancer types, and the key strategies and developments by the prominent vaccine market stake holders.
• What are the major market drivers, challenges, and opportunities in the global vaccine market?
• What are the underlying structures resulting in the emerging trends within the vaccine industry?
• What were the market values of the leading segments and sub-segments of the global vaccine market in 2017?
• How will each segment of the global vaccine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period 2018-2028?
• What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?
• What are the key vaccine type in vaccine market? What are the major benefits of each type?
• How has the market been segmented on the basis of disease type? Which disease type is dominating the global vaccine market, and what is the reason behind its domination?
• What are the market shares of each of the companies in the global vaccine market, and what are their contribution?
• Who are the key manufacturers in the global vaccine market, and what are their contributions?
• What is the scope of each vaccine type, route of administration, and disease type in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?
• What are the key regulatory implications in developed and developing regions for vaccines?
• What is the growth potential of vaccine in each region, including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?
• Which vaccine type is having the most promising growth and in which disease type?
The key players who have been contributing significantly to the global vaccine market are Merck &Co., Inc., GlaxoSmithKline plc, Abbott Laboratories, Bavarian Nordic, Janssen Pharmaceutical NV, Pfizer, Inc., Sanofi Pasteur SA, and Seqirus (a CSL company), among others.
List of Tables
Table 2.1 Impact Analysis
Table 2.2 Vaccination Coverage (by Vaccine and WHO Region) - Worldwide, 2016
Table 3.1 Number of Mergers and Acquisitions (by Each Company), January 2015-September 2018
Table 3.2 Number of Business Expansion (by Each Company), January 2015-September 2018
Table 4.1 The European Medicines Agency’s Scientific Guidelines on Vaccines
Table 4.2 Regulatory Scenario Across the World
Table 7.1 Global Vaccine Market (by Disease Type), 2017-2028
Table 8.1 North America Vaccine Market (by Disease Type), 2017-2028
Table 8.2 Europe Vaccine Market (by Disease Type), 2017-2028 ($Billion)
Table 8.3 APAC Vaccine Market (by Disease Type), 2017-2028 ($Billion)
Table 8.4 Latin America Vaccine Market (by Disease Type), 2017-2028 ($Billion)
Table 8.5 Middle East and Africa Vaccine Market (by Disease Type), 2017-2028 ($Billion)
List of Figures
Figure 1 Global Vaccine Market Structure
Figure 2 Impact of Market Drivers and Market Restraints, 2017 and 2028
Figure 3 Global Vaccine Market Snapshot
Figure 4 Dominating Segments of Global Vaccine Market, 2017 and 2028
Figure 5 Global Vaccine Market (by Vaccine type), 2017 and 2028
Figure 6 Global Vaccine Market (by Route of Administration), 2017 and 2028
Figure 7 Global Vaccine Market (by Region), 2017 and 2028
Figure 8 Global Vaccine Market (by Region), 2017 and 2028
Figure 9 Market Statistics
Figure 10 Market Share Analysis: Global Vaccine Market, 2017
Figure 11 Opportunity Map Analysis of Next-generation Vaccines
Figure 1.1 Classification of Global Vaccine Market
Figure 1.2 Different Types and Generation of Vaccines
Figure 1.3 Components of a Vaccine
Figure 1.4 Evolution of Vaccines against Diseases
Figure 1.5 Global Vaccine Market, 2017-2028
Figure 2.1 Market Dynamics of Global Vaccine Market
Figure 3.1 Competitive Landscape, January 2015-September 2018
Figure 3.2 Share of Key Developments and Strategies, January 2015-September 2018
Figure 3.3 Product Launches Share (by Companies), January 2015- September 2018
Figure 3.4 Joint Ventures, Partnerships, and Collaborations Share (by Companies), January 2015-September 2018
Figure 3.5 Others Share (by Companies), January 2015-September 2018
Figure 3.6 Market Share Analysis: Global Vaccine Market, 2016 and 2017
Figure 3.7 Porter’s Five Forces Analysis
Figure 3.8 Bargaining Power of Suppliers: Overall Impact, 2015-2028
Figure 3.9 Bargaining Power of Buyers: Overall Impact, 2015-2028
Figure 3.10 Threat of New Entrant: Overall Impact, 2015-2028
Figure 3.11 Threat of Substitute Products: Overall Impact, 2014-2028
Figure 3.12 Intensity of Competitive Rivalry: Overall Impact, 2015-2028
Figure 4.1 Industry Insights, January 2015-May 2018
Figure 4.2 Regulatory Pathway from Preclinical to the Marketing Authorization
Figure 4.3 Pipeline Analysis
Figure 4.4 Pipeline Analysis According to Clinical Trial Phases
Figure 5.1 Global Vaccine Market (by Route of Administration)
Figure 5.2 Global Vaccine Market (by Route of Administration), 2017-2028
Figure 5.3 Global Vaccine Market (by Intramuscular), 2017-2028
Figure 5.4 Global Vaccine Market (by Subcutaneous), 2017-2028
Figure 5.5 Global Vaccine Market (by Oral Vaccine), 2017-2028
Figure 5.6 Global Vaccine Market (by Intravenous vaccine), 2017-2028
Figure 5.7 Global Vaccine Market (by Others), 2017-2028
Figure 6.1 Global Vaccine Market (by Type)
Figure 6.2 Global Vaccine Market (by Type), 2017-2028
Figure 6.3 Global Vaccine Market (by Subunit and Conjugate), 2017-2028
Figure 6.4 Global Vaccine Market (by Live Attenuated), 2017-2028
Figure 6.5 Global Vaccine Market (by Inactivated), 2017-2028
Figure 6.6 Global Vaccine Market (by Recombinant), 2017-2028
Figure 6.7 Global Vaccine Market (by Toxoid), 2017-2028
Figure 6.8 Global Vaccine Market (by Next-Generation), 2021-2028
Figure 7.1 Global Vaccine Market (by Disease Type)
Figure 7.2 Global Vaccine Market (by Pneumococcal Disease), 2017-2028
Figure 7.3 Global Pneumococcal Disease Vaccine Market (by Region), 2017-2028
Figure 7.4 Global Vaccine Market (by DTP), 2017-2018
Figure 7.5 Global DTP Disease Vaccine Market (by Region), 2017-2028
Figure 7.6 Global Vaccine Market (by Influenza), 2017-2028
Figure 7.7 Global Influenza Vaccine Market (by Region), 2017-2028
Figure 7.8 Global Vaccine Market (by Cancer), 2017-2028
Figure 7.9 Global Cancer Vaccine Market (by Region), 2017-2028
Figure 7.10 Global Vaccine Market (by HPV), 2017-2028
Figure 7.11 Global HPV Vaccine Market (by Region), 2017-2028
Figure 7.12 Global Vaccine Market (by Meningococcal Disease), 2017-2028
Figure 7.13 Global Meningococcal Disease Vaccine Market (by Region), 2017-2028
Figure 7.14 Global Vaccine Market (by Hepatitis), 2017-2028
Figure 7.15 Global Hepatitis Disease Vaccine Market (by Region), 2017-2028
Figure 7.16 Global Vaccine Market (by MMR), 2017-2028
Figure 7.17 Global MMR Vaccine Market (by Region), 2017-2028
Figure 7.18 Global Vaccine Market (by Rotavirus), 2017-2028
Figure 7.19 Global Rotavirus Vaccine Market (by Region), 2017-2028
Figure 7.20 Global Vaccine Market (by Varicella), 2017-2028
Figure 7.21 Global Varicella Vaccine Market (by Region), 2017-2028
Figure 7.22 Global Vaccine Market (by Others), 2017-2028
Figure 8.1 Global Vaccine Market (by Region), 2017 and 2028
Figure 8.2 Global Vaccine Market (by Vaccine Market), 2017-2028
Figure 8.3 North America Vaccine Market, 2017-2028
Figure 8.4 North America: Market Dynamics
Figure 8.5 North America Vaccine Market (by Country), 2017-2028
Figure 8.6 North America Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.7 North America Vaccine Market (by Route of Administration), 2017-2028
Figure 8.8 U.S. Vaccine Market, 2017-2028
Figure 8.9 Canada Vaccine Market, 2017-2028
Figure 8.10 Europe Vaccine Market, 2017-2028
Figure 8.11 Europe: Market Dynamics
Figure 8.12 Europe Vaccine Market (by Country), 2017-2028
Figure 8.13 Europe Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.14 Europe Vaccine Market (by Route of Administration), 2017-2028
Figure 8.15 Germany Vaccine Market, 2017-2028
Figure 8.16 France Vaccine Market, 2017-2028
Figure 8.17 U.K. Vaccine Market, 2017-2028
Figure 8.18 Spain Vaccine Market, 2017-2028
Figure 8.19 Italy Vaccine Market, 2017-2028
Figure 8.20 Switzerland Vaccine Market, 2017-2028
Figure 8.21 Rest-of-Europe Vaccine Market, 2017-2028
Figure 8.22 APAC Vaccine Market, 2017-2028
Figure 8.23 APAC: Market Dynamics
Figure 8.24 APAC Vaccine Market (by Country), 2017-2028
Figure 8.25 APAC Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.26 APAC Vaccine Market (by Route of Administration), 2017-2028
Figure 8.27 China Vaccine Market, 2017-2028
Figure 8.28 India Vaccine Market, 2017-2028
Figure 8.29 Japan Vaccine Market, 2017-2028
Figure 8.30 Australia Vaccine Market, 2017-2028
Figure 8.31 South Korea Vaccine Market, 2017-2028
Figure 8.32 Rest-of-APAC Vaccine Market, 2017-2028
Figure 8.33 Latin America Vaccine Market, 2017-2028
Figure 8.34 Latin America: Market Dynamics
Figure 8.35 Latin America Vaccine Market (by Country), 2017-2028
Figure 8.36 Latin America Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.37 Latin America Vaccine Market (by Route of Administration), 2017-2028
Figure 8.38 Brazil Vaccine Market, 2017-2028
Figure 8.39 Mexico Vaccine Market, 2017-2028
Figure 8.40 Rest-of-Latin America Vaccine Market, 2017-2028
Figure 8.41 Middle East and Africa Vaccine Market, 2017-2028
Figure 8.42 Middle East and Africa: Market Dynamics
Figure 8.43 Middle East and Africa Vaccine Market (by Country), 2017-2028
Figure 8.44 Middle East and Africa Vaccine Market (by Vaccine Type), 2017-2028
Figure 8.45 Middle East and Africa Vaccine Market (by Route of Administration), 2017-2028
Figure 8.46 GCC Vaccine Market, 2017-2028
Figure 8.47 South Africa Vaccine Market, 2017-2028
Figure 8.48 Rest-of- Middle East and Africa Vaccine Market, 2017-2028
Figure 9.1 Share of Key Company Profiled
Figure 9.2 Abbott India Ltd. (Subsidiary of Abbott Laboratories): Product Offerings for Global Vaccine Market
Figure 9.3 Abbott Laboratories: Overall Financials, 2015-2017
Figure 9.4 Abbott Laboratories: Revenue (by Business Segment), 2015-2017
Figure 9.5 Abbott Laboratories: Revenue (by Region), 2015-2017
Figure 9.6 Abbott Laboratories: R&D Expense, 2015-2017
Figure 9.7 Abbott Laboratories: Revenue Forecast, 2015-2020
Figure 9.8 Abbott Laboratories: SWOT Analysis
Figure 9.9 AstraZeneca plc: Product Offerings for Global Vaccine Market
Figure 9.10 AstraZeneca plc: Overall Financials, 2015-2017
Figure 9.11 AstraZeneca plc: Revenue (by Region), 2015-2017
Figure 9.12 AstraZeneca plc: R&D Expense, 2015-2017
Figure 9.13 AstraZeneca PLC: SWOT Analysis
Figure 9.14 BiondVax Pharmaceuticals Ltd.: Overall Financials, 2015-2017
Figure 9.15 BiondVax Pharmaceuticals Ltd.: R&D Expense, 2015-2017
Figure 9.16 BiondVax Pharmaceuticals Ltd.: SWOT Analysis
Figure 9.17 Bavarian Nordic: Overall Financials, 2015-2017
Figure 9.18 Bavarian Nordic: Revenue (by Region), 2015-2017
Figure 9.19 Bavarian Nordic: R&D Expense, 2015-2017
Figure 9.20 Bavarian Nordic: Revenue Forecast, 2015-2020
Figure 9.21 Bavarian Nordic: SWOT Analysis
Figure 9.22 CSL Limited: Product Offerings for Global Vaccine Market
Figure 9.23 CSL Limited: Overall Financials, 2015-2017
Figure 9.24 CSL Limited: Revenue (by Business Segment), 2015-2017
Figure 9.25 CSL Limited: Revenue (by Region), 2015-2017
Figure 9.26 CSL Limited: R&D Expense, 2015-2017
Figure 9.27 CSL Limited: Revenue Forecast, 2015-2020
Figure 9.28 CSL Limited: SWOT Analysis
Figure 9.29 Daiichi Sankyo Company, Limited: Product Offerings for Global Vaccine Market
Figure 9.30 Daiichi Sankyo Company, Limited: Overall Financials, 2015-2017
Figure 9.31 Daiichi Sankyo Company, Limited: Revenue (by Business Segment), 2015-2017
Figure 9.32 Daiichi Sankyo Company, Limited: Revenue (by Region), 2015-2017
Figure 9.33 Daiichi Sankyo Company, Limited: R&D Expense, 2015-2017
Figure 9.34 Daiichi Sankyo Company, Limited: Revenue Forecast, 2015-2020
Figure 9.35 Daiichi Sankyo Company, Limited: SWOT Analysis
Figure 9.36 Emergent BioSolutions Inc.: Product Offerings for Global Vaccine Market
Figure 9.37 Emergent BioSolutions Inc.: Overall Financials, 2015-2017
Figure 9.38 Emergent BioSolutions Inc.: Revenue (by Region), 2015-2017
Figure 9.39 Emergent BioSolutions Inc.: R&D Expense, 2015-2017
Figure 9.40 Emergent BioSolution Inc.: Revenue Forecast, 2015-2020
Figure 9.41 Emergent BioSolutions Inc.: SWOT Analysis
Figure 9.42 GlaxoSmithKline plc: Product Offerings for Global Vaccine Market
Figure 9.43 GlaxoSmithKline plc: Overall Financials, 2015-2017
Figure 9.44 GlaxoSmithKline plc: Revenue (by Business Segment), 2015-2017
Figure 9.45 GlaxoSmithKline plc: Revenue (by Region), 2015-2017
Figure 9.46 GlaxoSmithKline plc: R&D Expense, 2015-2017
Figure 9.47 GlaxoSmithKline plc: Revenue Forecast, 2015-2020
Figure 9.48 GlaxoSmithKline plc: SWOT Analysis
Figure 9.49 Product Offerings
Figure 9.50 Inovio Pharmaceuticals Inc.: Overall Financials, 2015-2017
Figure 9.51 Inovio Pharmaceuticals Inc..: R&D Expense, 2015-2017
Figure 9.52 Inovio pharmaceuticals Inc.: Revenue Forecast, 2015-2020
Figure 9.53 Inovio Pharmaceutical Inc.: SWOT Analysis
Figure 9.54 Johnson & Johnson: Product Offerings for Global Vaccine Market
Figure 9.55 Johnson & Johnson: Overall Financials, 2015-2017
Figure 9.56 Johnson & Johnson: Revenue (by Business Segment), 2015-2017
Figure 9.57 Johnson & Johnson: Revenue (by Region), 2015-2017
Figure 9.58 Johnson & Johnson: R&D Expense, 2015-2017
Figure 9.59 Johnson & Johnson: Revenue Forecast, 2015-2020
Figure 9.60 Johnson & Johnson: SWOT Analysis
Figure 9.61 Merck & Co. Inc.: Product Offerings for Global Vaccine Market
Figure 9.62 Merck & Co: Overall Financials, 2015-2017
Figure 9.63 Merck & Co. Inc..: Revenue (by Business Segment), 2015-2017
Figure 9.64 Merck & Co. Inc..: Revenue (by Region), 2015-2017
Figure 9.65 Merck & Co. Inc..: R&D Expense, 2015-2017
Figure 9.66 Merck & Co. Inc..: Revenue Forecast, 2015-2020
Figure 9.67 Merck & Co. Inc.: SWOT Analysis
Figure 9.68 Madison Vaccines Incorporated: SWOT Analysis
Figure 9.69 Pfizer, Inc.: Product Offerings for Global Vaccine Market
Figure 9.70 Pfizer, Inc.: Overall Financials, 2015-2017
Figure 9.71 Pfizer, Inc.: Revenue (by Business Segment) 2015-2017
Figure 9.72 Pfizer, Inc.: Revenue (by Region) 2015- 2017
Figure 9.73 Pfizer, Inc.: R&D Expense, 2015-2017
Figure 9.74 Pfizer, Inc.: Revenue Forecast, 2015-2020
Figure 9.75 Pfizer, Inc.: SWOT Analysis
Figure 9.76 Sanofi S.A.: Product Offerings for Global Vaccine Market
Figure 9.77 Pipeline Products
Figure 9.78 Sanofi S.A.: Overall Financials, 2015-2017
Figure 9.79 Sanofi S.A..: Revenue (by Business Segment), 2015-2017
Figure 9.80 Sanofi S.A.: Revenue (by Region), 2015-2017
Figure 9.81 Sanofi S.A.: R&D Expense, 2015-2017
Figure 9.82 Sanofi S.A..: Revenue Forecast, 2015-2020
Figure 9.83 Sanofi S.A..: SWOT Analysis
Figure 9.84 Sinovac Biotech Ltd.: Product Offerings for Global Vaccine Market
Figure 9.85 Sinovac Biotech Ltd..: Overall Financials, 2015-2017
Figure 9.86 Sinovac: Revenue (by Region), 2015-2017
Figure 9.87 Sinovac Biotech Ltd.: R&D Expense, 2015-2017
Figure 9.88 Sinovac Biotech Ltd.: Revenue Forecast, 2015-2020
Figure 9.89 Sinovac Biotech Ltd.: SWOT Analysis
Figure 9.90 Valneva SE: Product Offerings for Global Vaccine Market
Figure 9.91 Valneva SE.: Overall Financials, 2015-2017
Figure 9.92 Valneva SE: Revenue (by Business Segment), 2015-2017
Figure 9.93 Valneva SE: Revenue (by Region), 2015 & 2017
Figure 9.94 Valneva SE: R&D Expense, 2015-2017
Figure 9.95 Valneva SE: Revenue Forecast, 2015-2020
Figure 9.96 Valneva SE.: SWOT Analysis
Figure 9.97 VBI Vaccine Inc.: Product Offerings for Global Vaccine Market
Figure 9.98 VBI Vaccine Inc.: Overall Financials, 2015-2017
Figure 9.99 VBI Vaccine Inc. Revenue (by Region) 2015-2017
Figure 9.10 0 VBI Vaccine Inc.: R&D Expense, 2015-2017
Figure 9.10 1 VBI Vaccine Inc.: SWOT Analysis
Figure 10.1 Global Vaccine Market: Market Segmentation
Figure 10.2 Global Vaccine Market Segmentation
Figure 10.3 Primary Research
Figure 10.4 Secondary Research
Figure 10.5 Data Triangulation
Figure 10.6 Top-down Approach (Segment-wise Analysis)
Figure 10.7 Bottom-up Approach (Segment-wise Analysis)
Figure 10.8 Assumptions and Limitations
Figure 10.9 Considered Factors for Data Prediction and Modelling
There has been a continuous search in the medical world for better treatment and prevention approaches for various infectious and non-infectious diseases. This paved the way for the most awaited change in pediatric and adult vaccines. In the recent years, the impressive research on biologics for the development of DNA, recombinant, and cancer vaccines with better routes of administration, has opened new hopes to develop promising vaccines for different types of cancers, rare, and orphan diseases. Recent advancements in vaccine technologies especially in vaccine delivery platforms and ongoing clinical trials have resulted in the evolution of therapeutic as well as preventive vaccines.
Vaccines play a major role in developing immune responses by imitating an infection. Depending on the type of infection either caused by bacteria or virus, different approaches are used by the researchers to develop vaccines. Vaccines have been fruitful in the treatment and prevention of cancer and large pool of infectious diseases such as influenza, hepatitis, meningitis, rotavirus, human papilloma virus (HPV), and dengue, among others. Cancer, a global pandemic, is one of the leading causes of deaths worldwide. According to the research study conducted by the International Agency for Cancer Research, approximately 14.1 million new cancer cases were detected, and 8.2 million cancer deaths were reported in 2012. Moreover, considering the present prevalence rates, the number of cases detected are expected to grow over 21.7 million while the death counts are expected to reach 13 million. The rise in the count of cancer cases has been significantly increasing the global economic burden and was estimated at $1.16 trillion in 2010. The ongoing clinical trials for the development of cancer vaccines is aimed at enabling early diagnosis and treatment, thus consequentially aiding in combating cancer. Additionally, rising outbreaks of epidemic and zoonotic diseases in different parts of the globe has led to the development of preventive vaccines that helps occurrence and spread of these infections to a significant extent.
The purpose of this study is to gain a holistic view of the vaccine market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global vaccine market. The market has been segmented into “vaccine type”, “route of administration”, “disease type”, and “region”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
The global vaccine market is anticipated to reach $103.57 billion by 2028, witnessing a CAGR of 11.02% in the forecast period 2018-2028. Some of the factors such as growing prominence for the rising need for immunization coverage, substantial investments made in the field of research and development of novel vaccines and technologies, growing demand for cancer vaccines, and increasing incidence of infectious diseases and cancer coupled with rising geriatric population are acting as significant factors propelling the growth of the global vaccine market.
In terms of vaccine type, the global vaccine market is dominated by subunit and conjugate vaccine. Subunit and conjugate vaccines were developed when inactivated and killed vaccines failed to show significant results in the treatment and prevention of several diseases. Subunit vaccines can comprise from one to 20 antigens or more at times. Moreover, subunit vaccines use recombinant DNA technology as well for the antigen biomolecules from microbes. There are different types of subunit vaccines that are currently available in the market such as protein-based subunit vaccines, polysaccharide vaccines, and subunit conjugate vaccines. Furthermore, they are used in the treatment and prevention of large number of diseases such as influenza, hepatitis b, haemophilus influenza type B, pertussis, pneumococcal infections, and meningococcal diseases.
In terms of route of administration, the global vaccine market is dominated by intramuscular. In 2017, the market for intramuscular route of administration was valued $18.03 billion. Vaccines that are currently available in the market are majorly administered intramuscularly. Furthermore, this route of administration is effective for all age groups.
In terms of regional potential, North America is the leading contributor to the global vaccine market and contributed approximately 35% of the global market values in 2017. This can be attributed to high adoption rate of advanced technologies, increasing healthcare investments, presence of major manufacturers and increasing research and clinical trials by researchers and scientists for development of new vaccines across various universities in the region.
The key players who have been contributing significantly to the global vaccine market are Pfizer, Inc., Merck & Co., Inc., Emergent Biosolutions Inc., Abbott Laboratories, VBI Vaccines Inc., Madison Vaccines, Vical Inc., Inovio Pharmaceuticals Inc., GlaxoSmithKline plc, CSL Limited, AstraZeneca plc, LG Chem Ltd., Daiichi Sankyo Company, Limited, Sanofi S.A., Valneva SE, Bavarian Nordic, Sinovac Biotech Ltd., and Janssen Pharmaceutica NV, among others.
We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.
With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.
Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.
